ZIOPHARM Oncology, Inc. (ZIOP)

Trade Setup

ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient’s immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies; and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate production of IL-12 to treat patients with recurrent glioblastoma multiforme in adults. 

Stocks found in this category are low priced stocks priced between .50 and $5, with at least 50k shares of average shares trading per day.   The stocks are pausing a trend either up or down, with a new bar over the prior day open or close.  These are high reward to risk stocks with the potential for very sharp moves.  A stop should be maintained at the low of the prior day.   Target prices for exits can be determined by using the next level of resistance higher or by using Fibonacci resistance levels found using TradersPro.


X